Is NVAX or OTLK more undervalued in 2026?

CirclFi compares Novavax, Inc. (NVAX) and Outlook Therapeutics, Inc. (OTLK) using 13 institutional-grade valuation models. NVAX has a Quality of Company score of 6.4/10 while OTLK scores 3.7/10.

Which is a better buy — NVAX or OTLK?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do NVAX and OTLK valuations compare?

NVAX at $10.97 and OTLK at $0.73 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

NVAX vs OTLK Valuation Comparison 2026 — Intrinsic Value Analysis

NVAX

Biological Products, (No Diagnostic Substances)

Novavax, Inc.

Quality

6.4

out of 10

Value Trap

SAFE

Price

$10.97

Last close

Models

10/13

Active

OTLK

Biological Products, (No Diagnostic Substances)

Outlook Therapeutics, Inc.

Quality

3.7

out of 10

Value Trap

LOW

Price

$0.73

Last close

Models

9/13

Active

Model-by-Model Comparison

Model	Type	NVAX Fair Value	NVAX Upside	OTLK Fair Value	OTLK Upside
Bayesian DCF	Intrinsic	$1.33	-87.9%	$0.07	-90.7%
Earnings Power Value	Intrinsic	$2.46	-69.6%	$0.17	-35.9%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for NVAX vs OTLK — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

NVAX vs OTLK — Which Stock Is More Undervalued?

NVAX scores higher with a 6.4/10 quality rating vs OTLK's 3.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Novavax, Inc. (NVAX) and Outlook Therapeutics, Inc. (OTLK) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

NVAX currently trades at $10.97 with a QOC of 6.4/10, while OTLK trades at $0.73 with a QOC of 3.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).